JDRF Blog

JDRF Blog

Information on research, events, activities, and news from the T1D community across Canada. 

Subscribe to the newsletter

Dear type 1, It's been a big adjustment.

Type 1 diabetes became a part of Danny Miller’s family’s life just 18 months ago when his son, Cody, was diagnosed.

Read More

Exploring the link between type 1 diabetes and depression

Exploring the link between type 1 diabetes and depression

Young people living with a chronic illness like type 1 diabetes (T1D) often experience anxiety which – if not treated – can quickly spiral downwards into depression. However, the link between diabetes and depression remains poorly understood and under-researched. Depression is often view...


JDRF youth ambassador sets out to change the future of type 1 diabetes

JDRF youth ambassador sets out to change the future of type 1 diabetes

Meet Noah Silvaggio, an ambitious 16-year-old JDRF youth ambassador who was voted one of Manitoba’s Top 40 Young People to Watch in 2018 in the category of community activism and social affairs.


Implant of differentiated pluripotent stem cells to treat diabetes

Implant of differentiated pluripotent stem cells to treat diabetes

Dr. Timothy Kieffer, a JDRF-funded investigator and professor in the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia, has been awarded a new two-year grant to continue his research involving insulin-producing cells as a potential ...


Clinical trials of islet and stem cell therapies for type 1 diabetes

Clinical trials of islet and stem cell therapies for type 1 diabetes

Clinical islet transplantation is viewed as a viable treatment that has the potential to eliminate a life-long dependence on insulin in individuals with type 1 diabetes (T1D). Dr. Shapiro breaks down the three areas his research study will focus on.


Regulatory T cells (Tregs) and their function in T1D

Regulatory T cells (Tregs) and their function in T1D

Dr. Anne Maria Pesenacker, a JDRF-funded investigator at the University of British Columbia and now at UCL’s Institute of Immunity and Transplantation, is examining how regulatory T cells (Tregs) function in health and how best to monitor their fitness.


First European clinical trial in human stem cell therapy for type 1 diabetes is underway

First European clinical trial in human stem cell therapy for type 1 diabetes is underway

The development of encapsulation technologies to treat insulin-dependent diabetes has been at the forefront of type 1 diabetes (T1D) research in North America for many years. This is because new methods of cell delivery may offer a functional cure for people with T1D at high risk for life-threating ...


How to raise money for Walk using social media

How To Raise Money for Walk using Social Media

It goes without saying that social media has become the way we share snippets of our lives. Not only has it revolutionized how we get a glimpse into those of our friends and family, but it has radically changed how we learn about the world around us, how we engage with government and how we unite to...


Advocate Profile: Memorial University of Newfoundland medical students

Advocate Profile: Memorial University of Newfoundland medical students

Guest blog post by Nguyet (Na) Nguyen and Sarah Strong The Provincial Day of Action is a yearly event where medical students identify a gap in the healthcare system and approach our provincial government with an “ask” to help fix that gap. This year, as students in the Faculty of Medi...


The 2019 federal budget and you

The 2019 federal budget and you

While the 2019 Canadian budget was eagerly anticipated by all Canadians, there were items that directly impacted members of the type 1 diabetes (T1D) community. So what does the 2019 federal budget mean for you?


Advocate Profile: Ashlynn O'Hara and not backing down from the #AccessforAll fight

Advocate Profile: Ashlynn O'Hara and not backing down from the #AccessforAll fight

Ashlynn O’Hara is 10 years old, lives with type 1 diabetes (T1D), and is taking her fight for affordable continuous glucose monitors (CGM) to the big leagues.


Lets turn type one into type none